Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics: FDA wants survival-benefit trial before tovecimig BLA filing

Negative Impact 4 of 5 legal/regulatory Written later

Compass Therapeutics said the FDA recommended it conduct a trial demonstrating a survival benefit before submitting a Biologics License Application for tovecimig in previously treated advanced biliary tract cancer. The company said it does not believe a new trial is warranted before submission and will keep engaging with the FDA, which means the timing and path to approval are now uncertain.

Key points

  • FDA recommended a trial demonstrating a survival benefit before a BLA submission for tovecimig
  • Phase 2/3 COMPANION-002 showed ORR of 18.0% vs. 5.3% with paclitaxel alone (p=0.0228)
  • Median progression-free survival was 4.7 vs. 2.6 months, hazard ratio 0.44 (p<0.0001)
  • Overall survival analyses did not reach statistical significance due to crossover

The filing

CompanyCompass Therapeutics, Inc. (CMPX)
Form8-K, current report
Filed with the SECSep 22, 2026, 8:30 AM ET
Accession number0001171843-26-006162

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.